A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with renal impairment compared to matched control participants with normal renal function.

2022-500775-31-00 Protocol DC09RUP/1/21 Human pharmacology (Phase I) - Other Ended

Start 8 Nov 2022 · End 24 Oct 2025 · Status Ended · 2 EU/EEA countries · 7 sites · Protocol DC09RUP/1/21

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 48
Countries 2
Sites 7

Allergic rhinitis

Key facts

Sponsor
Noucor Health S.A.
Participant type
Patients, Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Respiratory Tract Diseases [C08]
Trial duration
8 Nov 2022 → 24 Oct 2025
Decision date (initial)
2022-09-08
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Allergic rhinitis

VersionLevelCodeTermSystem organ class
21.1 LLT 10001723 Allergic rhinitis 10038738
20.0 PT 10046735 Urticaria 100000004858

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Noucor Health S.A.

Sponsor organisation
Noucor Health S.A.
Address
Avinguda Del Cami Reial 51-57
City
Palau-Solita I Plegamans
Postcode
08184
Country
Spain

Scientific contact point

Organisation
Noucor Health S.A.
Contact name
Daniel Peris

Public contact point

Organisation
Noucor Health S.A.
Contact name
Daniel Peris

Locations

2 EU/EEA countries · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
Portugal Ended 24 3
Spain Ended 24 4
Rest of world 0

Investigational sites

Portugal

3 sites · Ended
Blueclinical Investigacao E Desenvolvimento Em Saude Lda.
BlueClinical Phase I, East Wing, Rua De Sarmento De Beires 153 3rd Floor 4 Floor, Porto
Centro Hospitalar De Vila Nova De Gaia Espinho
Early Phase Clinical Trial Unit | CHVNG/E + BlueClinical, Rua Conceicao Fernandes, 4434-502, Vila Nova De Gaia
Hospital Pedro Hispano
Early Phase Clinical Trials Unit | ULSM+BlueClinical, Rua Doutor Eduardo Torres 1, 4450-113, Matosinhos

Spain

4 sites · Ended
Municipal Institute Of Medical Investigation
Unidad de Investigación Clínica del IMIM, Calle Del Doctor Aiguader 80, 08003, Barcelona
Hospital Universitari Germans Trias I Pujol
Nephrology, Ctra. Canyet S/n, Edificio General 1a Planta, Badalona
Hospital De La Santa Creu I Sant Pau
Drug Research Center, Calle De San Antonio Maria Claret 167, 08025, Barcelona
Hospital Universitario De La Princesa
Clinical Pharmacology, Calle De Diego De Leon 62, 28006, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Portugal 2022-11-08 2022-11-21 2024-12-11
Spain 2022-12-12 2023-01-16 2024-07-04

Application history

9 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2022-06-03 Spain Acceptable
2022-07-26
2022-08-01
2 NON SUBSTANTIAL MODIFICATION NSM-1 2023-02-01 Spain Acceptable
2022-07-26
2023-02-01
3 NON SUBSTANTIAL MODIFICATION NSM-2 2023-03-22 Acceptable
2022-07-26
2023-03-22
4 SUBSTANTIAL MODIFICATION SM-1 2023-03-23 Spain Acceptable
2023-06-05
2023-06-05
5 NON SUBSTANTIAL MODIFICATION NSM-3 2024-02-07 Spain Acceptable
2023-06-05
2024-02-07
6 SUBSTANTIAL MODIFICATION SM-2 2024-04-30 Spain Acceptable
2024-06-10
2024-06-10
7 SUBSTANTIAL MODIFICATION SM-3 2024-06-18 Spain Acceptable
2024-07-19
2024-07-19
8 SUBSTANTIAL MODIFICATION SM-4 2024-12-18 Spain Acceptable
2025-01-29
2025-01-29
9 NON SUBSTANTIAL MODIFICATION NSM-4 2025-02-05 Spain Acceptable
2025-01-29
2025-02-05